[Monksdream]

Early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

[subslover]

Theseus Pharmaceuticals explores strategic options; cuts workforce by 72%

[TheFinalCD]

under the radar today https://finviz.com/quote.ashx?t=THRX&p=d

[stocktrademan]

$THRX recent news/filings

bullish

## source: finance.yahoo.com

Fri, 26 Jun 2015 23:04:07 GMT ~ HTML PDF

[at noodls] - GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 06/02/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ('Theravance Biopharma' or the 'Company') announced today that stock options to purchase an aggregate ...

read full: http://www.noodls.com/view/27B9EC8E05AFA214C736275DDCFC104CA2893262
*********************************************************

Fri, 05 Jun 2015 13:16:00 GMT ~ 5 Biotech Stocks Poised for Breakouts


read full: http://www.thestreet.com/story/13176437/1/5-biotech-stocks-poised-for-breakouts.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Tue, 02 Jun 2015 21:09:11 GMT ~ Theravance Biopharma Announces New Employment Inducement Awards

[at noodls] - GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 06/02/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ('Theravance Biopharma' or the 'Company') announced today that stock options to purchase an aggregate ...

read full: http://www.noodls.com/view/152E7A1B96FBF4C57130F918FB5AB36C85A1A062
*********************************************************

Wed, 27 May 2015 12:29:08 GMT ~ Theravance Biopharma and SciClone Pharmaceuticals Enter Into Development and Commercialization Agreement for VIBATIV(R) (Telavancin) in China

[at noodls] - GEORGE TOWN, GRAND CAYMAN and FOSTER CITY, CA -- (Marketwired) -- 05/27/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ('Theravance Biopharma'), through an affiliate, and SciClone Pharmaceuticals (NASDAQ: ...

read full: http://www.noodls.com/view/D7C534DF2A1F08DCF33BFB704692586B17BD0DCC
*********************************************************

Wed, 27 May 2015 12:19:06 GMT ~ SciClone Pharmaceuticals and Theravance Biopharma Enter Into Development and Commercialization Agreement for VIBATIV(R) (Telavancin) in China

[at noodls] - FOSTER CITY, CA and GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 05/27/15 -- SciClone Pharmaceuticals (NASDAQ: SCLN), ('SciClone'), a U.S.-based, China-focused specialty pharmaceutical company, and Theravance ...

read full: http://www.noodls.com/view/639BEFAFB1ED0E4FE9B4097F361D422957200C8D
*********************************************************

$THRX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$THRX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/THRX/company-info
Ticker: $THRX
OTC Market Place: Not Available
CIK code: 0001080014
Company name: Theravance, Inc.
Company website: http://www.theravance.com
Incorporated In: DE, USA


$THRX share structure

## source: otcmarkets.com

Market Value: $2,263,824,838 a/o Jun 26, 2015
Shares Outstanding: 116,872,733 a/o Apr 30, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01

$THRX extra dd links

Company name: Theravance, Inc.
Company website: http://www.theravance.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/THRX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/THRX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=THRX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=THRX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=THRX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/THRX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/THRX/news - http://finance.yahoo.com/q/h?s=THRX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/THRX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/THRX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/THRX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/THRX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/THRX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/THRX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/THRX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/THRX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=THRX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/THRX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Theravance%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Theravance%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Theravance%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.theravance.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.theravance.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.theravance.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/THRX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/THRX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/THRX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/THRX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/THRX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001080014&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/THRX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/THRX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/THRX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/THRX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=THRX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=THRX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/THRX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=THRX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=THRX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=THRX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=THRX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=THRX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/THRX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=THRX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/THRX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=THRX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/THRX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/THRX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/THRX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/THRX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/THRX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/THRX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/THRX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=THRX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=THRX



$THRX DD Notes ~ http://www.ddnotesmaker.com/THRX

[surf1944]

9:02AM Theravance and GlaxoSmithKline (GSK) announce BREO ELLIPTA is now available to pharmacies throughout the U.S.; THRX agreed to make a milestone payment of $30 mln to GSK (THRX) :

GlaxoSmithKline plc (GSK) and Theravance (THRX) announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), is now available to pharmacies throughout the U.S.
BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2-agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg). It is indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. BREO ELLIPTA is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.
Under the terms of its 2002 LABA collaboration agreement with GSK, Theravance agreed to make a milestone payment of $30 mln (USD) to GSK following the launch of BREO ELLIPTA in the U.S.

[surf1944]

3:18AM Theravance and GlaxoSmithKline (GSK) announce that RELVAR ELLIPTA gains approval in Japan for the treatment of asthma (THRX) 41.20 : GlaxoSmithKline (GSK) and Theravance (THRX) announce that the Japanese Ministry of Health, Labour and Welfare has approved RELVAR ELLIPTA for the treatment of bronchial asthma (in cases where concurrent use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required). Relvar Ellipta is not indicated for the treatment of chronic obstructive pulmonary disease in Japan.

Under the terms of the 2002 LABA collaboration agreement, Theravance is obligated to make a milestone payment of $10 mln to GSK following MHLW approval of Relvar Ellipta in Japan.

[surf1944]

7:18AM Theravance halted; FDA Advisory Committee to review ANORO ELLIPTA NDA (THRX) 37.79 : Co announced that NASDAQ halted trading of Theravance common stock this morning, Sep 10, 2013. The Pulmonary-Allergy Drugs Advisory Committee to the FDA meets today to discuss the new molecular entity New Drug Application (NDA) 203975 for umeclidinium bromide and vilanterol dry powder for inhalation (proposed trade name ANORO ELLIPTA), sponsored by Glaxo Group (GSK) (d/b/a GSK) for the long-term, once-daily, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. UMEC/VI is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide, a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist (LABA), administered using the ELLIPTA inhaler. UMEC/VI is in development under the LABA collaboration agreement between Glaxo Group and Theravance.

[JD400]

GSK shares hit as Advair generics edge closer in U.S.

LONDON (Reuters) - The threat of generic copies of GlaxoSmithKline's (GSK.L) best-selling lung drug Advair finally making it to market in the United States hit confidence in the drug maker on Tuesday, sending the stock down more than 3 percent.

Fears of cheaper versions of the $8 billion-a-year seller being launched in the world's biggest market were fuelled by a draft guidance document from the Food and Drug Administration setting out the requirements for generic versions of the inhaled drug.

Bernstein analyst Tim Anderson said the requirements looked "fairly benign" for generic firms seeking to make copies that could be automatically substituted for Advair when patients have their prescriptions filled.

Citigroup said its worst-case scenario for an accelerated U.S. Advair sales decline, following the FDA document, could slice up to 5 percent off GSK's valuation.

http://finance.yahoo.com/news/gsk-shares-hit-advair-generics-082354075.html?l=1

Advair, which is marketed as Seretide outside the United States, is used to treat both asthma and chronic lung disease caused by smoking.

Although patents on the active ingredients used in the medicine have expired, it remains protected by U.S. patents on the Diskus inhaler device that run until 2016, after which copies may reach the market.

Up until now, many investors had assumed that fully substitutable generic versions of Advair were unlikely in the United States and instead generics would have to compete as separate brands. The FDA pathway to permitting "true" generics therefore represents a heightened threat.

Shares in GSK were down 3.3 percent at 15.85 pounds by 0805 GMT (3:05 EDT).

The uncertainty over Advair comes on the same day that a U.S. advisory panel is due to consider a new lung drug called Anoro from GSK and Theravance (THRX).

[surf1944]

8:05AM Theravance Announces Reintroduction of VIBATIV (telavancin) to the U.S. Market (THRX) 36.80 : Co announces that it has commenced shipments of VIBATIV (telavancin) into the US wholesaler channel. VIBATIV is approved in the US for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable, and for the treatment of complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including Staphylococcus aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains.

[surf1944]

12:38PM Theravance and GlaxoSmithKline (GSK) confirm BREO ELLIPTA gains U.S. approval for the treatment of COPD (THRX) 34.59 +3.28 : GlaxoSmithKline plc (GSK) and Theravance (THRX) announced that the FDA has approved BREO ELLIPTA as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2 agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg). Following this approval by the FDA, it is anticipated that BREO ELLIPTA will be available in the US during the third quarter of 2013. Under the terms of the 2002 LABA collaboration agreement, Theravance is obligated to make a milestone payment of $30 million (USD) to GSK following FDA approval of BREO ELLIPTA.

[starbuxsux]

Theravance to Split Into Two Companies, Swings to 1st-Quarter Loss

Apr 25, 2013 17:23:34 (ET)




By Nathalie Tadena

Theravance Inc. (THRX) said it plans to create two independent publicly traded companies, separating its late-stage partnered respiratory assets from its biopharmaceutical operations.

Shares of the company, which had been halted ahead of the news, jumped 8.3% to $33.50 after hours. Through the close, the stock has climbed 45% over the past three months.

Theravance said one company will focus on managing the rights to potential respiratory product royalty revenues under its collaboration with GlaxoSmithKline PLC (GSK, GSK.LN). This company is expected to retain Theravance's net operating loss carryforwards and intends to return capital to shareholders.

The other company will be a separate biopharmaceutical company focusing on the development and commercialization of small-molecule medicines. Theravance said it plans to capitalize this company with about $300 million at separation, which is expected to fund operations over the following two to three years.

Theravance's current Chief Executive Rick Winningham will initially serve as CEO of the royalty management company. Most of Theravance's current employees are expected to become employees of the biopharmaceutical operations-focused company.

The separation is expected to be completed by late 2013 or early 2014.

Theravance also reported it swung to a first-quarter loss of $37.4 million, or 39 cents a share, from a year earlier profit of $84.6 million. Revenue from collaborative arrangements declined 99% to $1.3 million, primarily due to the termination of its collaboration with Astellas Pharma for the development and commercialization of Vibativ in January 2012.

Analysts polled by Thomson Reuters had expected a per-share loss of 38 cents and revenue of $2 million.

Write to Nathalie Tadena at [e-mail]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

April 25, 2013 17:23 ET (21:23 GMT)

[gixxer11]

Agreed - possibly a couple gap fills in the short term

[surf1944]

Most all the good news is in THRX, on Sell list

[surf1944]

4:00PM Theravance confirms FDA Advisory Committee recommends approval of BREO ELLIPTA for the treatment of COPD (stock halted) (THRX) 28.01 : Co and GlaxoSmithKline (GSK) announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against). BREO ELLIPTA, is the proposed proprietary name for FF/VI 100/25 mcg, a combination of the inhaled corticosteroid (ICS) fluticasone furoate "FF" and the long acting bronchodilator (LABA) vilanterol "VI" (FF/VI). The FDA Advisory Committee also voted that the safety of FF/VI 100/25 mcg once daily in COPD has been adequately demonstrated for the proposed indications (10 for, 3 against). The FDA Advisory Committee provides non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA. The Prescription Drug User Fee Act (PDUFA) goal date for FF/VI is 12 May 2013.

[gixxer11]

What link do you have - Tia

[John Q Trader]

LOL I am watching this FDA hearing, and cant make sense from any of this clinical mumbo jumbo. JUST GIVE ME THE BOTTOM LINE PLEASE :)

[surf1944]

7:09AM Theravance shares halted; The Pulmonary-Allergy Drugs Advisory Committee to the FDA meets today to discuss the new drug application 204275, for fluticasone furoate and vilanterol dry powder inhaler, sponsored by GlaxoSmithKline (GSK) (THRX) :

[surf1944]

CORRECTED-UPDATE 2-FDA reviewers give mixed views on Glaxo lung drug

FDA reviewers say data for Glaxo's BREO not consistent
8:30am EDT

Mon Apr 15, 2013 11:30am EDT
(Changes headline to reflect that FDA reviewers, not advisory panel, gave opinion on drug)

* FDA reviewers: efficacy data not entirely consistent

* Say safety data generally consistent with other products

* Analysts interpret FDA reviewer opinions positively

* Theravance shares up 22 pct; Glaxo up 3.7 pct

By Toni Clarke

WASHINGTON, April 15 (Reuters) - Reviewers for the U.S. Food and Drug Administration said on Monday that efficacy data for an experimental drug made by GlaxoSmithKline Plc and Theravance Inc was somewhat inconsistent but that its overall safety appears consistent with similar drugs, a relief to investors.

GSK's shares were up 3.7 percent at 1,628 pence on Monday while shares of the smaller Theravance were up 22 percent at $28.98.

The drug, Breo, treats a lung disease that causes breathing difficulties and includes chronic bronchitis, emphysema, or both.

The reviewers' opinions were posted on the FDA's website ahead of a meeting scheduled for Wednesday in which a panel of expert advisers will discuss the drug and recommend whether it should be approved. Their views were interpreted in a generally positive way by investment analysts.

"The FDA review is benign and a relief given the issues that emerged in this clinical trial programme," said Alistair Campbell, an analyst at Berenberg Bank in a research note.

Breo is made up of 100 micrograms of a corticosteroid, fluticasone furoate (FF), and 25 micrograms of a long-acting beta-agonist, or LABA, called vilanterol (VI). The drug is administered via a new dry powder inhaler called Ellipta.

The FDA's advisory panel will be examining whether the benefits of Breo outweigh the risks, and whether the drug combination confers additional benefit over and above the LABA component alone.

"On the positive side, the FDA appears happy with the dosing for Breo, which has marginally increased the probability of approval in our opinion," said Jeffrey Holford, an analyst at Jefferies, in a research note. He estimates peak annual sales of the drug in COPD of $1.5 billion.

COPD refers to a group of lung diseases that block airflow and make breathing difficult. Emphysema, which is most frequently caused by smoking, and chronic bronchitis, an inflammation of the lining of the bronchial tubes, are the two most common conditions that make up COPD.

COPD became the third-leading cause of death in the United States in 2008, according to the U.S. Centers for Disease Control and Prevention, affecting more than 12 million Americans.

The reviewers questioned the contribution of the corticosteroid in improving lung function, saying the data was inconsistent, though they suggested the data appears to support a benefit in limiting COPD exacerbations.

They said the drug's safety profile appears generally consistent with that of similar drugs, though they pointed out an increase in cases of pneumonia and fractures.

"The main question mark appears to be the relative benefit of adding a steroid onto the bronchodilator," said Berenberg's Campbell.

He said he expects the advisory panel meeting "may be less contentious than feared and this should give Breo a very good chance of a positive recommendation."

Glaxo owns 27 percent of Theravance and speculation has risen that Glaxo might buy the remaining 73 percent in order to gain full control of their portfolio of jointly developed respiratory drugs.

The market for COPD drugs has until now been dominated by Glaxo's Advair and Pfizer Inc's Spiriva. Glaxo is seeking a successor to Advair, its twice-daily medication for COPD and asthma which generates some $8 billion a year. (Editing by Maureen Bavdek and Matthew Lewis)

[surf1944]

7:02AM Theravance and GlaxoSmithKline (GSK) announce FDA acceptance of New Drug Application submission in the US for ANORO ELLIPTA for COPD (THRX) 22.13 : Co and GlaxoSmithKline (GSK) announced that the New Drug Application (NDA) for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD), has been accepted by the FDA indicating that the application is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) goal date has also been confirmed as 18 December 2013.

[surf1944]

7:11AM Theravance Announce and GlaxoSmithKline plc (GSK) regulatory submission for UMEC/VI (LAMA/LABA) in the US (THRX) 22.08 : GlaxoSmithKline plc (GSK) and Theravance (THRX) announced the submission of a regulatory application in the US for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD).

UMEC/VI is a combination of two investigational bronchodilator molecules -- GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist, administered using the ELLIPTA inhaler.

US Submission:
A New Drug Application for UMEC/VI (62.5/25mcg and 125/25mcg doses) with the proposed proprietary name ANORO ELLIPTA has been submitted to the US Food and Drug Administration, for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.

Future Regulatory Submissions:
Regulatory filings for UMEC/VI are planned in the European Union imminently and in other countries during the course of 2013. In addition, GSK intends to commence global regulatory submissions for UMEC monotherapy in the ELLIPTA inhaler for COPD patients in 2013.

[starbuxsux]

Halted...

[surf1944]

THRX FDA PanelThu, November 29, 12am – Fri, November 30, 12am
Calendar
FDA Calendar

[surf1944]

I am currently in about 75 small cap biotech stocks & looking to add on any weakness in the weeks. Hopeful for a major bounce in many beaten down stocks, but the whole sector should do well into Jan/Feb, this bounce has taken place since I have been following the group. Most are less than $10/share, but again THRX will rise with the sector....

[hm36tm]

Which stocks are you looking for an year end bounce?

[starbuxsux]

I would love to see some of those tickers that apply to that statement and compare them with mine lol

I play tax selling plays this time of the year, stocks that have been killed with likely moves of over 100% into Jan

[surf1944]

THRX may trend higher into Jan, but the risk reward is not in it for me with the large number of other biotech stocks starting to move move up. I play tax selling plays this time of the year, stocks that have been killed with likely moves of over 100% into Jan, THRX doesn't fit that line of thinking for me....

[starbuxsux]

Your thoughts on this one?